NovaBay Announces Positive Phase I Study Results with Its Lead Aganocide Compound
Product Shown to be Safe as First Step Towards Its Potential Use in Controlling MRSA in Hospitals
28-Nov-2007 -
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial and viral infections, reports results from a Phase I trial studying the lead Aganocide compound, NVC-422, a novel non-antibiotic anti-infective that has ...
absorption
anti-infectives
Staphylococcus aureus
+1